By Andrew Silver SHANGHAI (Reuters) -Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

In response, Novo is reorganizing its leadership team following the surprise ouster of Chief Executive Lars Fruergaard ...

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...

Sonia Saxena’s five-year weight loss journey transformed her from an overwhelmed mother at 80 kg to a disciplined, empowered ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...

Participants’ weight stayed about the same during the trial, suggesting that headache reductions weren’t tied to weight loss. If the results hold up in larger studies, they may point to treatments for ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

A novel medication out of Sweden has shown some of the same promise in melting belly fat — without making your stomach churn.